Inside MedSpa — Daily Brief, 2026-07-14
The few things that actually moved in your field — distilled. The headlines are free. The so-what is for subscribers.
1Steel Partners bids $16.75/share for InMode; device supply chain enters M&A volatility
What happenedSteel Partners, an existing InMode shareholder, made an unsolicited $16.75-per-share cash offer to acquire the medical-device company, challenging a concurrent CEO-led buyout proposal. InMode confirmed receipt and is evaluating both offers.
2Medicare to negotiate Botox pricing; neuromodulator economics shift downward
What happenedMedicare announced it will negotiate the price of Botox and 14 other drugs this year, as part of the Inflation Reduction Act's drug-pricing authority. Negotiated prices are expected to take effect in 2027.
3Evolus adds Profhilo to portfolio; skin-quality category intensifies competitive pressure
What happenedEvolus secured an exclusive 15-year U.S. licensing agreement with IBSA to develop and commercialize Profhilo, a hybrid HA biostimulator injectable. The deal includes no upfront payment, with Evolus handling distribution and marketing.
4Cynosure launches next-generation monopolar RF in Europe; U.S. market entry likely within 12 months
What happenedCynosure Lutronic introduced a new monopolar RF platform (XERF) in Europe, marketed for non-invasive skin tightening. The device represents the next iteration of RF technology and is positioned to address rising patient demand for body and facial tightening.
5L'Oréal raises Galderma stake to 20%; strategic consolidation signals M&A momentum in aesthetics
What happenedL'Oréal increased its ownership stake in Galderma to 20%, signaling deeper strategic alignment and potential for further consolidation. Galderma is a major injectable and device manufacturer (Restylane, Sculptra, Radiesse, Zimmer).
This is one morning. Get it every morning.
The full brief — what each item means for your business and exactly what to do about it — lands in your inbox twice a week. $20 a month. Never miss the developments and rule changes that matter.
Get the brief — $20/mo